PROCEPT BioRobotics® to Present at Upcoming 37th Annual Piper Sandler Healthcare Conference on December 2, 2025
PROCEPT BioRobotics (Nasdaq: PRCT) announced management will present at the 37th Annual Piper Sandler Healthcare Conference in New York City on Tuesday, December 2, 2025 at 8:30 a.m. ET.
A live webcast and archived recording will be available in the company’s Investors section at https://ir.procept-biorobotics.com, with replays accessible for at least 90 days after the event.
PROCEPT BioRobotics (Nasdaq: PRCT) ha annunciato che la direzione parteciperà alla 37ª Piper Sandler Healthcare Conference a New York City martedì 2 dicembre 2025 alle 8:30 ET.
Una trasmissione in diretta e una registrazione archiviata saranno disponibili nella sezione Investitori dell'azienda all'indirizzo https://ir.procept-biorobotics.com, con i replay accessibili per almeno 90 giorni dopo l'evento.
PROCEPT BioRobotics (Nasdaq: PRCT) anunció que la dirección presentará en la 37ª Conferencia Anual de Piper Sandler Healthcare en la ciudad de Nueva York el martes 2 de diciembre de 2025 a las 8:30 a.m. ET.
Una transmisión en vivo y una grabación archivada estarán disponibles en la sección de Inversores de la empresa en https://ir.procept-biorobotics.com, con las repeticiones accesibles durante al menos 90 días después del evento.
PROCEPT BioRobotics (나스닥: PRCT)은 경영진이 뉴욕시에서 열리는 제37회 Piper Sandler Healthcare Conference에 2025년 12월 2일 화요일 동부 표준시 오전 8:30에 발표할 예정이라고 발표했습니다.
라이브 생방송 및 보관된 녹화본은 회사의 투자자 섹션에서 https://ir.procept-biorobotics.com 에서 이용 가능하며, 이벤트 이후 최소 90일간 재생 가능합니다.
PROCEPT BioRobotics (Nasdaq : PRCT) a annoncé que la direction participera à la 37e conférence annuelle Piper Sandler Healthcare à New York le mardi 2 décembre 2025 à 8h30, heure de l'Est.
Une diffusion en direct et un enregistrement archivé seront disponibles dans la section Investisseurs de la société à l'adresse https://ir.procept-biorobotics.com, les rediffusions étant accessibles pendant au moins 90 jours après l'événement.
PROCEPT BioRobotics (Nasdaq: PRCT) hat bekannt gegeben, dass das Management an der 37. Piper Sandler Healthcare Conference in New York City am Dienstag, dem 2. Dezember 2025 um 8:30 Uhr EST teilnehmen wird.
Ein Live-Webcast und eine archivierte Aufzeichnung werden im Bereich Investoren des Unternehmens unter https://ir.procept-biorobotics.com verfügbar sein, mit Wiederholungen für mindestens 90 Tage nach der Veranstaltung.
PROCEPT BioRobotics (ناسداك: PRCT) أعلنت الإدارة أنها ستشارك في المؤتمر الصحي السنوي الـ37 لبير ساندلر في مدينة نيويورك يوم الثلاثاء 2 ديسمبر 2025 في الساعة 8:30 صباحاً بتوقيت شرق الولايات المتحدة.
سيكون البث المباشر ونسخة مسجلة متاحة في قسم المستثمرين بالشركة على العنوان https://ir.procept-biorobotics.com، مع إمكانية الوصول إلى الإعادة لمدة لا تقل عن 90 يوماً بعد الحدث.
- None.
- None.
SAN JOSE, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 37th Annual Piper Sandler Healthcare Conference in New York City. Management is scheduled to present on Tuesday, December 2 at 8:30 a.m. Eastern Time.
A live webcast of each event, as well as an archived recording, will be available on the “Investors” section of the Company’s website at: https://ir.procept-biorobotics.com. The webcasts will be archived and available for replay for at least 90 days after the event.
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics’ mission is to revolutionize BPH treatment globally in partnership with urologists by delivering best-in-class robotic solutions that positively impact patients and drive value. PROCEPT BioRobotics manufactures the AQUABEAM® and HYDROS® Robotic Systems. The HYDROS Robotic System is the only AI-Powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. The Company has developed a significant and growing body of clinical evidence with over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.
Investor Contact:
Matt Bacso
VP, Investor Relations and Business Operations
m.bacso@procept-biorobotics.com
FAQ
When will PROCEPT BioRobotics (PRCT) present at the Piper Sandler Healthcare Conference?
Where can I watch the PROCEPT BioRobotics (PRCT) live webcast for the December 2 presentation?
How long will the PROCEPT BioRobotics (PRCT) presentation recording be available after the Piper Sandler event?
Will PROCEPT BioRobotics (PRCT) provide slides or materials during the December 2 presentation?
What time zone is used for the PROCEPT BioRobotics (PRCT) presentation schedule?
